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Abstract
Introduction: The Chronic Infantile Neurological Cutaneous and Articular (CINCA, or Neonatal-onset multisystem
inflammatory disease NOMID) is a rare autoinflammatory disease identified in 1987 by Prieur et al., typically
characterized by the triad of skin rash, arthropathy and central nervous system manifestations. It represents the
most severe phenotype of the cryopyrin-associated periodic syndrome (CAPS).
Clinical description and etiology: The syndrome is due to autosomal dominant gain of function mutations in
NLRP3, which encodes a key component of the innate immunity that regulates the activation and secretion of
interleukin (IL)-1β. From the first days of life, patients display an urticarial rash in association with chronic
inflammation with a typical facies featured by frontal bossing and saddle back nose. The CNS manifestations
include chronic aseptic meningitis leading to brain atrophy, mental delay and sensorineural hearing loss. Chronic
polyarthritis and alteration of the growth cartilage also may be present. CINCA/NOMID diagnosis is made clinically,
based on the presence of characteristic features. The detection of NLRP3 mutations is diagnostic in 65–70% of
cases. Indeed, up to 40% of affected patients are negative for germline NLRP3 mutations and several subjects are
carriers of somatic mosaicism. Due to the pivotal role of Cryopyrin in the control of Caspase-1 activation and the
massive secretion of active IL-1β observed in cryopyrin-mutated individuals, anti-IL1 treatment represents the
standard therapy.
Conclusion: Prognosis of CINCA/NOMID syndrome has been changed by the availability of anti-IL1 drugs.
Nowadays, the use of anti-IL-1 drugs has sensibly reduced the risk of developing main complications such as severe
intellectual disability, hearing-loss and amyloidosis, if treatment is started early on.
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Background
Cryopyrin-associated periodic syndromes (CAPS) are
inherited autoinflammatory conditions characterized by
chronic systemic inflammation due to an abnormal regu-
lation of the innate immune system. Three diseases of
rising severity belong to this group: Familial Cold Auto-
inflammatory Syndrome (FCAS), Muckle-Wells syn-
drome (MWS) and Chronic Infantile Neurological
Cutaneous and Articular (CINCA, or Neonatal-Onset
Multisystem Inflammatory Disease, NOMID), with the
latter being the most severe form of CAPS spectrum.
Disease onset usually occurs within the first hours/days
of life and it is characterized by intermittent fever (that
may be of low grade or even absent), urticarial rash and
persistent elevation of acute phase reactants. A neuro-
logical involvement featured by chronic aseptic meningi-
tis and papilledema is usually present at disease
presentation and may lead to brain atrophy, severe intel-
lectual disability and hearing loss. Hypertrophic arthrop-
athy with contractures and bone deformity (frontal
bossing, patellar overgrowth) is also typical of this form.
Disease name/synonyms
Chronic infantile neurological cutaneous and articular
(CINCA) syndrome is also called Neonatal onset multi-
systemic inflammatory disease (NOMID), Infantile-onset
multisystem inflammatory disease (IOMID) and Prieur-
Griscelli syndrome (OMIM 607115).
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Definition and classification
CINCA/NOMID syndrome is the prototype of an inher-
ited autoinflammatory disorder due to mutation of a gene
encoding the NLPR3 (or cryopyrin) protein, which is in-
volved in the activation of the inflammatory response. It
belongs to the group of the so-called inflammasome-
pathies, together with other conditions associated to mu-
tations of genes that are members of the same protein
family (NLRP12, NLRC4, NLRP12).
Epidemiology
It is estimated that globally the whole spectrum of CAPS
has a prevalence of 1–2 cases in every 1 million [1] and
360,000 [2] people in the US and France, respectively.
According to a prospective surveillance of children with
CAPS performed in Germany during a time period of
3 years by Lainka et al., the incidence of CAPS in
Germany corresponds to 2–7 newly diagnosed patients
≤16 years per year [3].
Clinical description
CINCA/NOMID syndrome represents the most severe
phenotype in the context of the clinical spectrum of
CAPS (Table 1).
In a recent study by Levy et al. [4] the whole spectrum
of CAPS in adult and pediatric patients has been de-
scribed in a large series of 136 patients enrolled in the
Eurofever International Registry. The median onset age
was 0.8 years (range 0.1–5) while the median age at
diagnosis was 15 years (range 5–36) with a mean delay
of diagnosis of 14 years. Seventy-eight patients (57%)
had a chronic course with symptoms almost daily,
whereas fifty-eight (43%) experienced only acute epi-
sodes. Fever, skin rash and musculoskeletal involvement
were the most prevalent features (observed in 84, 97 and
86% of patients, respectively) and were observed in all
the 3 diseases (FCAS, MWS and CINCA/NOMID).
In general, CINCA/NOMID children present during
the first days of life with a chronic urticarial rash associ-
ated to persistent low-grade fever and sustained eleva-
tion of acute phase reactants. The rash is non-pruritic
and it changes distribution during the day, without vas-
culitic alterations (Fig. 1).
Patients display a typical “facies”, featured by frontal
bossing, large cephalic perimeter and saddle-back nose
(Fig. 2).
If untreated, these patients develop permanent CNS
damages as consequence of chronic inflammation [5].
Chronic aseptic meningitis may cause intracranial pres-
sure to increase, resulting in hydrocephalus, brain atro-
phy and chronic papilledema (Fig. 3). Neurological
symptoms typical of CINCA/NOMID are characterized
by chronic irritability, intellectual disability, headache,
early morning nausea, vomiting and, rarely, seizures. In
the Eurovefer registry the most frequent severe neuro-
logical manifestation was chronic meningitis, that was
observed in 26% of patient. Other major neurological
features (seizures, hydrocephalus, mental delay) were re-
ported in 12% of the whole CAPS population.
The most frequent inflammatory eye manifestation is
conjunctivitis. Persistent papilledema is rather common
and it may cause optic nerve atrophy with progressive
vision loss if left untreated [6, 7]. Anterior uveitis can
contribute to the progressive vision loss. In the study of
Dollfus et al. [8] the ocular manifestations in CINCA/
NOMID patients (n = 31) were described with a mean
follow up of 11.5 years (2 to 32 years). The first ocular
sign occurred at the mean age of 4.5 years (1–9 years),
and it was represented by red eyes (n = 9), decreased vi-
sion (n = 7), strabismus (n = 4), nystagmus (n = 2) and
photophobia (n = 2). During follow-up, 8 patients com-
plained visual loss, all of them had signs of optic nerve
lesion (i.e. optic disc edema in 2 patients and optic atro-
phy in 6 subjects), while 6 had also corneal involvement.
In most patients, anterior ocular inflammation was fea-
tured by a mild to moderate anterior uveitis (9 out of 16
patients), while posterior inflammation seemed to occur
less frequently. Optic disc abnormalities occurred in 26
patients (84%) and included optic disc edema and, less
frequently, pseudopapilledema and optic atrophy. Anter-
ior segment manifestations were observed in 13 patients
(42%). Disease-related visual acuity loss in at least 1 eye
Table 1 Cryopyrin associated periodic syndrome (CAPS): main clinical features
Familial cold autoinflammatory
syndrome (FCAS)
Muckle–Wells syndrome (MWS) NOMID/CINCA












• AA amyloidosis (in 25% of patients)




• Visual and intellectual damage
• Sensorineural deafness
• Progressive chronic meningitis
• Destructive arthritis
• AA amyloidosis leading to renal failure
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was reported in 8 patients (26%). Posterior synechia, glau-
coma, and white iritis were not observed in any patient.
Persistent cochlear inflammation may lead to sensori-
neural hearing loss usually occurs within the first years
of life in a relevant percentage of untreated patients
(42% of CAPS patients enrolled in Eurofever Registry,
Levy et al.). In a prospective study performed in 2013 by
Neda Ahmadi et al. [9], data regarding clinical aspects,
audiologic phenotype and fluid attenuation inversion re-
covery MRI (FLAIR-MRI) were collected in CAPS
patients (n = 57) including 31 CINCA/NOMID subjects.
Complete audiological data were obtained in 70% of ears
and displayed conductive, mixed and sensorineural
hearing loss in 11, 13 and 61% of CINCA/NOMID ears,
respectively. The latter was worse in the higher frequen-
cies. Cochlear enhancement on FLAIR-MRI sequences was
observed mainly in CINCA/NOMID (n = 26) and it ap-
peared to be an accurate predictor of cochlear hearing loss.
Approximately 60% of CINCA/NOMID patients have
prominent arthropathy, most frequently involving large
joints as knees [10]. It usually begins during childhood
and causes deformities that persist in adult age, resulting
in early degenerative arthropathy and joint contractures.
Histological analysis of growth cartilage displays a
complete disorganization and irregular metachromasia
of cartilage substance, but no inflammatory cell infil-
trates [11]. In a 2007 study by Hill et al., radiographs
were performed in a total of 20 CINCA/NOMID pa-
tients and bone abnormalities were detected in 11 out of
20 knees of patients. These findings included enlarge-
ment and deformities of femora and patellae in all the
patients, without evidence of synovitis. The mechanism
leading to articular damage is likely represented by an
abnormal endochondral bone formation. Patellar prema-
ture ossification and overgrowth are typical, although
rare, findings in CINCA/NOMID [7]. A chronic polyar-
thritis may also be present, sometimes leading to bone
erosions. The multisystemic involvement characteristic
of CINCA/NOMID syndrome has a severe impact on
the quality of patient life [12].
Aetiology-genetics
As aforementioned, CINCA/NOMID represents the
most severe phenotype of CAPS, monogenic diseases
due to autosomal dominant inheritance of mutations in
the NLRP3 gene (formerly known as cold-induced auto-
inflammatory syndrome 1, CIAS1), which encodes the
NLRP3 protein also termed cryopyrin. NLRP3 variants
causing CAPS are missense mutations resulting in a gain
of function that, thus, enhance NLRP3 activity. To date,
approximately 170 NLRP3 variants have been described
and associated to either CINCA/NOMID or to milder
phenotypes of the NLRP3-driven clinical spectrum in-
cluding FCAS and MWS (http://fmf.igh.cnrs.fr/ISSAID/
infevers/) [9]. Almost all the NLRP3 mutations so far
identified have been observed within the exon 3, which
is responsible for encoding the NACHT domain, crucial
for cryopyrin oligomerization. However, although pa-
tients with FCAS and MWS tend to show familial inher-
itance patterns, CINCA/NOMID syndrome usually
occurs de novo, and approximately 50–65% the patients
with a CINCA/NOMID phenotype lack detectable muta-
tions in the NLRP3 coding region [13–16]. It has been
suggested that different genes or a modifier gene could
Fig. 1 Urticarial rash of CAPS patient
Fig. 2 Typical CINCA/NOMID “facies” featured by frontal bossing,
large cephalic perimeter and saddle-back nose
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be involved in these latter cases, although they do not
differ clinically from those carrying NLRP3 mutations.
In the past few years somatic NLRP3 mosaicism ra-
ther than heterozygous germ-line mutation has been
detected in up to 69.2% [17] of patients presenting
symptoms typical of CINCA/NOMID [17–22]. Thus,
for a majority of genetically negative CINCA/NOMID
patients, the disease onset may be caused by low-level
mosaicism in the absence of detectable NLRP3 gene
mutations by ordinary genomic sequencing [18–20].
NLRP3 mosaicism is thus an established major cause
of CINCA/NOMID [17]. However, only recently, in-
sights regarding the relevance of this mechanism were
provided in other CAPS phenotypes [23, 24]. Namely,
a variable degree (5.5–34.9%) of somatic NLRP3 mo-
saicism vertical transmission was detected in patients
with a MWS phenotype, pointing at somatic NLRP3
mosaicism as shared genetic mechanism in the whole
CAPS spectrum, not restricted to CINCA/NOMID
clinical picture [23, 24].
Aetiology- pathophysiology
The main functional effect of genetic background caus-
ing CAPS is the abnormal activation of innate immunity
cells by endogenous and exogenous stimuli. CAPS may
be considered the prototype of monogenic autoinflam-
matory diseases that, compared to autoimmune condi-
tions, are featured by an apparent secondary role of the
adaptive branch of the immune response, as suggested
by the lack of self-reactive T cells and/or circulating
autoantibodies and by the absence of a clear class II
MHC association [25]. NLRP3 actually belongs to
Nucleotide-binding domain and Leucine-rich repeat
containing Receptor (NLRs) family (also known as
Nucleotide-binding Oligomerization Domain (NOD)–
Like Receptors), which act as cytosolic pattern-
recognition receptors (PRRs) [26]. As a NLRs member,
NLRP3 physiologically functions as danger sensor and
undergoes activation following several insults, including
both exogenous Pathogen-Associated Molecular Patterns
(PAMPs) and the endogenous Damage-Associated
Fig. 3 MR features of CINCA/NOMID brain (subdural fluid collections, leptomeningeal contrast, papilledema, coclear enhancement)
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Molecular Patterns (DAMPs) [27, 28]. Once triggered,
NLRP3 interacts with other intracellular proteins and as-
semblies into a multiprotein complex called Inflamma-
some, a key player in IL-1β pathway activation. Unlike
most cytokines, indeed, the pro-inflammatory IL-1β
lacks a secretory signal peptide and it is released by
monocytes through a non canonical pathway including
two steps [29–31]. (Fig. 4) First, the 33-kD IL-1β precur-
sor pro-IL-1β is induced by bacterial products (e.g. lipo-
polysaccharide, LPS) and accumulates in the cytosol.
Secondarily, when a second hit triggers NLRP3, the in-
active pro-IL-1β is converted into its mature 17-kD form
[32]. Following activation, NLRP3 oligomerizes and
binds the adaptor Apoptosis-associated Speck-like pro-
tein containing a CARD (ASC) via its Pyrin (PYD)
domains. NLRP3-ASC complex then directly activates
pro-caspase1 into the active proteolytic enzyme cas-
pase1, which, in turn, cleaves the IL-1β and IL-18 pre-
cursors into their bioactive forms [32]. This tight and
complex control of IL-1β processing and secretion is
linked to the powerful properties of this proinflamma-
tory cytokine and it is necessary in order to avoid ad-
verse effects related to its excessive release [33, 34]. The
unrestrained IL-1β secretion occurring in CAPS patients
further proves this concept. CAPS, indeed, may be actu-
ally considered intrinsic cryopyrinopathies in which gain
of function mutations primarily affecting NLRP3 cause
cells to display a constitutively turned-on inflammasome
[35]. This condition releases inflammasome from the
need of a normally required second signal (i.e. ATP),
leading to caspase-1-driven IL-1β over-production [36].
Several data derived from either in vitro, in vivo and ex
vivo studies unveiled that NLRP3 mutations and redox
alterations work together in determining CAPS IL-1β
pattern of secretion. Indeed, factors inducing cellular
stress may give rise to persistent activation of innate im-
munity. In the presence of overly active danger sensor
such as NLRP3, it is conceivable that IL-1-mediated sig-
naling cascade may be enhanced. Reactive oxygen spe-
cies (ROS)-associated genes represent, indeed, one of
most differentially expressed set in severe CAPS [37].
For years, oxidative stress has been investigated as po-
tential key player in the activation of NLRP3-
inflammasome [34, 38]. NLRP3-mutated CAPS
monocytes basally display elevated levels of ROS and
fragmented mitochondria, and these stress marks are
dramatically worsened by TLR stimulation [39]. CAPS
resting monocytes also exhibit higher levels of antioxi-
dants, and redox response to PAMPs is also altered, with
faster upregulation of the antioxidant machinery which
rapidly undergoes exhaustion [40]. As result, CAPS pa-
tients are uniquely featured by a dramatically anticipated
IL1β secretion [40]. As aforementioned, once elicited,
IL-1β pathway disruption occurring in cryopyrinopathies
triggers a cascade of complex cellular events leading to
aberrant homeostatic tissue responses. In conclusion,
the research field exploring CINCA/NOMID path-
ogenesis is continuously in progress. A recent newly
Fig. 4 Schematic illustration of the NLRP3 inflammasome activation
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identified mechanism based on NLRP3 inflammasome
acting also as an extracellular oligomeric complex thus
causing persistent inflammatory response further expands
the growing complexity underlying CINCA/NOMID
pathogenesis and open the field to a wide spectrum of
cross-talking signaling potentially involved [41].
Diagnosis and diagnostic methods
The characteristic clinical picture, starting with a persist-
ent urticarial rash associated to systemic inflammation
signs during the first days or week of life usually leads to
the suspicion of a diagnosis CINCA/NOMID syndrome
[42]. The persistence of the symptoms despite the anti-
biotic and/or antiviral treatment and the partial control
of the symptoms achieved by steroids have to address
the suspicion through a cryopyrin associated periodic
syndrome. Even if laboratory alterations are not specific,
CINCA/NOMID patients may display persistent eleva-
tion of acute phase reactants, leukocytosis and chronic
anemia. Recently, evidence-based clinical criteria for
CAPS and other inherited periodic fevers have been de-
veloped, on the basis of the multivariate analysis per-
formed on a large number of patients enrolled in the
Eurofever international registry [43]. Even if these cri-
teria were developed in patients presenting a recurrent
disease course, 100% of the CINCA/NOMID patients
enrolled in the Eurofever registry were correctly identi-
fied. New specific criteria for CAPS, including the most
severe CINCA/NOMID phenotype are currently under
development (Kummerle et al., in preparation). In order
to confirm the diagnosis the molecular analysis of
NLRP3 gene is surely required. Due to the severe pheno-
type, usually de-novo mutations are detected. As already
stated, up to 35–40% of patients with a clear CINCA/
NOMID phenotype turn out to be negative for germ-
line mutations of NLRP3 [17]. Almost 70% of these pa-
tients are, instead, carriers of a somatic mosaicism [44],
that can involve even a very low percentage of the cells
of myeloid lineage [17]. There is a general consensus
among experts that the clinical picture of CINCA/
NOMID is sufficient to point out the diagnosis even in
the absence of a positive genetic test [45].
Differential diagnosis
The disease onset of CINCA/NOMID syndrome usually
occurs early on, often within the first months of life.
Therefore, in the beginning, an infectious disease is
often suspected. A diagnostic algorithm in children with
fever and skin rash has been recently developed in order
to differentiate CINCA/NOMID from the other cryopyr-
inopathies (FCAS and MWS) and autoinflammatory dis-
eases (i.e. CANDLE syndrome and systemic onset
juvenile idiopathic arthritis) characterized by a similar
clinical picture [42]. Patients with a severe form of
mevalonate kinase deficiency (MKD) may present a very
early onset with a chronic and subchronic disease
course. An urticarial skin rash can also be present, even
if without the daily occurrence observed in CAPS. TNF-
receptor associated periodic fever (TRAPS) usually
present with long lasting fever episodes followed by clin-
ical remission. An urticarial skin rash has been observed,
at least occasionally, in 25% of TRAPS patients enrolled
in the Eurofever registry [46]. However, the presence of
other more typical manifestations (erythematous migra-
tory rash, fasciitis, periobrital oedema, abdominal and
chest pain) help in the differentiation with CAPS. Due
to the lack of urticarial rash, other forms of periodic
fever, such as familiar Mediterranean fever (FMF) and
PFAPA (periodic fever with adenitis pharingitis and aph-
tosis) syndrome do not usually enter in the differential
diagnosis with CAPS.
Genetic counseling
Patients affected by CINCA/NOMID syndrome and car-
rying germinal mutation in NLRP3 gene have the chance
of 50% to transmit the disease to each child, since the
modality of transmission is autosomal dominant. In case
of somatic mosaicism this risk depends on the possible
presence of somatic mutations in reproductive organs in
the parents [23].
Antenatal diagnosis
In presence of an affected parent the search for the
NLRP3 mutations can be performed through prenatal
diagnosis techniques (chorionic villus sampling or am-
niocentesis). The availability of anti-IL-1 treatment has
dramatically changed the long-term prognosis and the
quality of life of CAPS patients with a mild and inter-
mediate phenotypes that are usually transmitted with
the typical autosomal pattern. Conversely, the presence
of a severe neurological involvement in patients with
CINCA/NOMID phenotype might be associated to the
possibility to develop various degree of neurological com-
plications and hearing loss, even with an adequate and
timely treatment (see below). As stated above this latter
condition is usually associated to the presence of de-novo
mutations or somatic mosaicisms. This should be carefully
considered in the process of genetic counseling, concern-
ing possible prenatal and/or pre-implantation genetic
diagnosis.
Management including treatment
The discovery of the mechanism of action of cryopyrin
in the control of caspase-1 activation and the aberrant
secretion of IL-1β observed in patients with this disease
suggested that IL-1 blockage might be an effective treat-
ment (Table 2).
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Initially, isolated case reports and small studies showed
the dramatic effects of IL-1 receptor antagonist
(anakinra) in the control of rash and other systemic
manifestations in MWS [45], FCAS [47] and CINCA/
NOMID [7, 36, 48] patients. The long-term efficacy and
safety of anakinra in CINCA/NOMID were described
two distinct studies conducted in Italy and France, re-
spectively [12, 49]. Namely, data derived from both ana-
lyses indicated that anakinra regimen was safe and
effective on the long-term, and that it was associated
with a dramatic amelioration of the quality of life [12].
Sibley et al. published an open-label, long-term follow-
up study on a cohort of 26 CINCA/NOMID patients
treated with anakinra 1–5 mg/kg/day for at least
36 months [5]. In particular, the study aimed at evaluat-
ing the efficacy and safety of anti-IL-1 therapy in con-
trolling systemic and organ-specific inflammation and in
preventing the progression of organ damage. Sustained
improvements in diary scores, parent’s/patient’s and phy-
sician’s global scores of disease activity, parent’s/patient’s
pain scores, and inflammatory markers were observed
during all the period of the study. Despite a general good
control of clinical manifestations (including hearing loss,
ocular manifestations and headache) and laboratory pa-
rameters, few patients displayed a persistent, although
mild, inflammation of CNS, and treatment with anti-IL-
1 did not prevent the progression of the bone involve-
ment. Overall, this study provided evidence of sustained
efficacy of anti-IL-1 in CINCA/NOMID without
occurrence of significant adverse effects for up to 5 years.
Anakinra was approved for the CINCA/NOMID form of
CAPS in children older than 8 months in the US in early
2013 and for all forms of CAPS (FCAS, Muckle-Wells
and CINCA/NOMID) in the EU in November 2013. The
same good results have been also achieved with other
newer anti-IL-1 including rilonacept (a fully human di-
meric fusion protein that incorporates the extra-cellular
domain of both IL-1 receptor components) and canaki-
numab (a fully human anti-interleukin-1β monoclonal
antibody that selectively blocks IL-1β). Since the efficacy
of rilonacept has been demonstrated only in patients
with the milder phenotype [50], this drug is approved
for FCAS or MWS patients older than 11 years in US.
Canakinumab is used subcutaneously at a starting dose
of 150 mg (or 2 mg/kg) every 8 weeks [51]. However, as
described in the following paragraphs, patients with
CINCA/NOMID syndrome often require a higher dose
(4 mg/kg) and frequency of administration [52, 53]
Canakinumab is now approved in Europe and US for the
use in all subtypes of CAPS in patients older than
2 years. The percentage of complete response to these
drugs is generally quite high. However, a partial re-
sponse, mainly related to a persistent elevation of acute
phase reactants despite a satisfactory control of the clin-
ical manifestations has been reported either with the use
of Anakinra and Canakinumab in the Eurofever registry
[54]. In Kuemmerle-Deschner et al. 2011 study [52], an
open-label, multicentre, phase III study evaluating the
Table 2 Results of the main studies analyzing the use of antiIL1 drugs in CINCA syndrome
Study Type of
study












et al. 2006 [7]
Open-
label
anakinra 18 CINCA 6 18/18 In 12 patients intracranial
pressure, protein levels and
white cells count decreased
significantly







36 14/14 Not evaluated




anakinra 26 CINCA 60 26/26 Significant decrease of CSF
leukocyte count at 36 and





rilonacept 101 CAPS (FCAS
or MWS)
18 Mean key symptom score at week
72 reduced from 2.6 to 0
Not evaluated

















canakinumab 6 CINCA 24 Full remissionc
at month 6: 0/6
Inflammatory remissiond at month
6: 4/6
6 months: 0/6
aCNS involvement: abnormal CSF leukocyte count; bcomplete response: absent or minimal disease activity at the global assessment with acute phase reactants
within the normal range; cFull remission: remission of patient-reported clinical components and measures of systemic inflammation and CNS inflammation; dIn-
flammatory remission: CRP ≤10 mg/L and global diary score remission
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safety and efficacy of canakinumab in the largest cohort
of CAPS subjects, 32 CINCA/NOMID patients received
subcutaneous canakinumab (i.e. 150 mg or 2 mg/kg
≤40 kg every 8 weeks) for up to 2 years, and changes
from baseline in clinically significant abnormality of
neurological, audiogram and ophthalmological assess-
ments were evaluated. Regarding neurological involve-
ment, 4 CINCA/NOMID patients had abnormal
findings at baseline (i.e. bilateral hearing loss, polyneur-
opathy, bilateral carpal tunnel syndrome, language-based
learning disability, chronic headache). The successive
neurological assessments performed in the next 2 years
during canakinumab therapy showed normalization of
these findings in one CINCA/NOMID patient. Concern-
ing audiological impairment, in 4 CINCA/NOMID pa-
tients (aged 3–24 years) the abnormal audiogram
findings remained unchanged despite the 2 years treat-
ment with canakinumab. Finally, the resolution of macu-
lar oedema was observed for 1 eye of a CINCA/NOMID
patient and clinical improvement in blepheratis was re-
corded in another CINCA/NOMID subject. Notably,
during this study almost 50% of CINCA/NOMID pa-
tients required an adjustment of the dose and/or fre-
quency of drug administration [52]. In a subsequent
open study conducted in Italy in patients previously en-
rolled in the aforementioned trial, the median dose of
canakinumab in CINCA/NOMID patients after
12 months was 4 mg/kg with a mean frequency of ad-
ministration of 5 weeks [53], suggesting that the initial
dose of canakinumab in CINCA/NOMID patients
should be higher than 2 mg/kg every 8 weeks, which, in-
stead, represents the staring dose in the milder forms of
CAPS spectrum such as FCAS and MWS. Due to the
extreme rarity of the disease, few data are available on
treatment of most severe CINCA/NOMID patients dur-
ing the first year of life. Unfortunately, this period is ab-
solutely critical because most of the cerebral damage
secondary to the persistent inflammation occurs right in
the early phases of the mental development. Thus, a cru-
cial point in CINCA/NOMID patients with severe
phenotype is the therapeutic management during the
first year of life. While, in fact, it has been demonstrated
in non-human primates that the diffusion of anakinra in
the CNS is proportional to the systemic dose, there is no
clear evidence regarding whether, and in which propor-
tion, the new anti-IL-1 drugs may be actually capable of
passing through the blood–brain barrier therefore allow-
ing to control the disease activity in the CNS in these
patients with more severe CINCA/NOMID phenotype.
Six patients were enrolled and treated with canakinumab
after anakinra withdrawal in a recent open-label study
[55]. In this study, all 6 patients required a dose escal-
ation (i.e. from 150 mg or 2 mg/kg in patients <40 Kg to
600 mg or 8 mg/kg in patients <40 Kg every 4 weeks).
Treatment with canakinumab improved symptoms and
serum inflammatory signs, although low-grade CNS
leukocytosis persisted in 4 patients and headaches was
still affecting 1 patient despite ongoing treatment. In pa-
tients with CINCA/NOMID that progressed into intel-
lectual disability, speech and psychomotor therapy were
often required. Hearing loss often led to the need of sup-
porting hearing devices or cochlear implants. Thus, the
daily clinical management of patients with CINCA/
NOMID is extremely complex and only recently,
evidence-based recommendations have been developed
with particular attention to the management of all form
of CAPS spectrum and other autoinflammatory diseases.
According to these recommendations, use of anti-IL-1 is
indicated for whole spectrum of CAPS, at any age (level
of evidence 1B-2A) and long-term IL-1 inhibition should
be started as early as possible in patient with active dis-
ease to prevent organ damage [56]. There is general con-
sensus on the opportunity to ask for a specific anti-IL-1
treatment also in those patients with a clinical picture
highly consistent with a CAPS phenotype that turned
out to be negative for germ-line mutations [45].
Prognosis
Intellectual disability is often enlightened as the main
relevant prognostic factor and it develops in the first
years of life. Its severity is proportional to the delay of
the diagnosis and of the beginning of appropriate anti-
IL-1 treatment. Prognosis of CINCA/NOMID syndrome
has been dramatically improved by the availability of
anti-IL-1 drugs. In the past, the life prognosis was sig-
nificantly affected by several complications, including
the development in the adult age of renal amyloidosis,
responsible for the occurrence of chronic renal failure.
Even if no direct evidences are available so far, it is con-
ceivable that the dramatic control of the systemic in-
flammation using anti-IL-1 will sensibly reduce the risk
of the occurrence of this complication. Lane et al. in
2013 described 4 CAPS patients with amyloidosis treated
with anti-IL-1 agents. Of the 4 patients, 1 had received a
renal transplant prior to initiation of this treatment; all
the remaining 3 patients have a resolution of proteinuria
over the follow-up period. However, 3 of the 4 patients
had a stable chronic kidney disease and in 1 patient dis-
ease progressed from stage 1 to stage 2 over the 11-
years follow-up period. These findings suggest that even
in patients with established amyloidosis, effective treat-
ment of the underlying syndrome can lead to improved
renal function and regression of amyloid, as long as
renal impairment is not too advanced at time of diagno-
sis [57]. It may be reasonable that patients that have
been treated since the first months of life will present a
consistent reduction of long-term complication. How-
ever the progression of hearing loss has been described
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even in children that received a prompt diagnosis and
treatment. In this line, more efforts are needed to pro-
vide evidence on the best possible treatment, dosage and
frequency of administration of anti-IL-1 treatment in
order to completely prevent the occurrence of these
complications.
Unresolved questions
CINCA/NOMID syndrome is a relatively new disease
and the research exploring the underlying pathogenetic
mechanisms is constantly growing. Moreover, while the
clinical outcome is known for those patients who did
not receive treatment with anti-IL-1, the outcome
through adulthood of the patients who received anti-IL-
1 treatment in the infancy is still unknown. Regarding
the new anti-IL-1 drugs, the percentage of these drugs
reaching the CNS and therefore the possibility to pre-
vent the development of intellectual disability and brain
atrophy, above all in young children, it is unclear.
Conclusion
CINCA/NOMID syndrome is a rare autoinflammatory
syndrome. Recently, the pivotal role of IL-1 in the dis-
ease pathogenesis allowed to develop standard therapy
with anti-IL-1 agents that have dramatically changed the
prognosis during last years.
Abbreviation
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